Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 6/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698663 | 1.00 | TYK2 (0.41) | TYK2TLR8KDM4ELMNAADORA3 | |
| SCHEMBL17194892 | 0.83 | TLR8 (0.44) | TYK2TLR8KDM4EGAAMEN1 | |
| SCHEMBL27241744 | 0.83 | SCN9A (0.42) | TYK2MEN1USP2KMT2AATM | |
| SCHEMBL20150274 | 0.82 | TYK2 (0.33) | TYK2TLR8AOC3CHRM2CHRM3 | |
| SCHEMBL31280017 | 0.82 | TYK2 (0.39) | TYK2TLR8KDM4ELMNANPC1 | |
| SCHEMBL17198724 | 0.79 | TYK2 (0.38) | TYK2TLR8GAAPARP1AOC3 | |
| SCHEMBL18415107 | 0.79 | TYK2 (0.40) | TYK2KDM4EGAANPC1PKM | |
| SCHEMBL24824796 | 0.79 | PIK3CA (0.33) | TLR8KDM4ELMNA | |
| SCHEMBL15690505 | 0.78 | KEAP1 (0.42) | TYK2TLR8KDM4EKMT2AKEAP1 | |
| SCHEMBL24823032 | 0.78 | FYN (0.32) | TYK2GAAMEN1KMT2AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727941-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| CN-120152968-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-22 | — | — | US | disclosed |
| WO-2024255885-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-12-19 | — | — | WO | disclosed |
| CN-113227071-B | Amide-substituted heterocyclic compounds for the treatment of disorders associated with modulation of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117794912-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337655-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11866414-B2 | Substituted heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117355514-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| WO-2022241171-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866414-B2 | Substituted heterocyclic compounds | TYK2, JAK2, STAT3 | TYK2 1/4885TLR8 247/4885KDM4E 2066/4885 |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | TYK2 1/4885TLR8 247/4885KDM4E 2066/4885 |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | TYK2 1/4885TLR8 247/4885KDM4E 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.